Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 7/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738352 | 0.82 | CDK2 (0.48) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL737377 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL688576 | 0.78 | CCNB2 (0.64) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL16086613 | 0.76 | SMN1; SMN2 (0.53) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL999731 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL2650788 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL2481820 | 0.72 | CCNB2 (0.56) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL1241542 | 0.71 | SMN1; SMN2 (0.50) | SMN1; SMN2CDK2CCNE1CDK1CDK4 | |
| SCHEMBL16086702 | 0.70 | SMN1; SMN2 (0.49) | SMN1; SMN2CDK2CCNE1CCNE2CDK1 | |
| SCHEMBL15740656 | 0.70 | KMT2A (0.41) | SMN1; SMN2ALDH1A1TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931718-B1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2931718-B1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2019-01-16 | — | — | EP | disclosed |
| US-9527838-B2 | 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527838-B2 | 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527838-B2 | 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150336946-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336946-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336946-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2931718-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2099777-B1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2015-08-12 | — | — | EP | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| WO-2008084043-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336946-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | GCK, HK2, GCKR | SMN1; SMN2 3803/4885CDK2 315/4885CCNE1 4100/4885 |
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | SMN1; SMN2 2536/4885CDK2 268/4885CCNE1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.